Loading...
•
Dec 31, 2023
Castle Biosciences Q4 2023 Earnings Report
Achieved strong top-line and test report volume growth, driven by consistent execution and strategic investments.
Key Takeaways
Castle Biosciences reported a strong fourth quarter and full-year 2023, with a 72% increase in Q4 revenue compared to the same period in 2022. The company delivered 20,284 total test reports in Q4, a 60% increase year-over-year. Full-year 2023 revenue reached $219.8 million, a 60% increase compared to 2022.
Revenues were $66.1 million, a 72% increase compared to $38.3 million during the same period in 2022.
Delivered 20,284 total test reports, an increase of 60% compared to 12,644 in the same period of 2022.
Net loss was $2.6 million, compared to a net loss of $20.6 million for the same period in 2022.
Adjusted EBITDA was $9.4 million, compared to $(10.4) million for the same period in 2022.
Forward Guidance
The Company anticipates generating between $235-240 million in total revenue in 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...